Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-634-0 | CAS number: 123-54-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Neurotoxicity
Administrative data
- Endpoint:
- neurotoxicity
- Remarks:
- subchronic
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Poor documentation.
Data source
Reference
- Reference Type:
- secondary source
- Title:
- Unnamed
- Year:
- 1 983
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- A series of studies was made to clarify the relationship of 2,4-Pentanedione to neurotoxicity in terms of neuropathy and relative neurotoxic potentials using electrophysiological methods. A 200 mg/kg dose was administered subcutaneously five days a weeks to one group of 8 rats. This program continued for 40 weeks. Electrophysiological studies of the effects of the compounds on the peripheral nerve were performed by measuring of maximum motor conduction velocities (MCV) and sensory conduction velocities (SCV) in the tail nerve of the rats. Residual latencies (RL), motor distal latencies (DL), amplitudes of the muscle action potentials (MAP) and amplitudes of nerve action potentials (NAP) were also estimated.
- GLP compliance:
- not specified
- Limit test:
- yes
Test material
- Reference substance name:
- Pentane-2,4-dione
- EC Number:
- 204-634-0
- EC Name:
- Pentane-2,4-dione
- Cas Number:
- 123-54-6
- Molecular formula:
- C5H8O2
- IUPAC Name:
- pentane-2,4-dione
- Details on test material:
- TS-Freetext:
no data
Constituent 1
Test animals
- Species:
- rat
- Strain:
- not specified
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- no data
Administration / exposure
- Route of administration:
- subcutaneous
- Vehicle:
- not specified
- Details on exposure:
- no data
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 5 days a week, 40 weeks
- Frequency of treatment:
- consecutive edays
Doses / concentrations
- Remarks:
- Doses / Concentrations:
200 mg/kg
Basis:
nominal conc.
- No. of animals per sex per dose:
- 8
- Control animals:
- not specified
- Details on study design:
- no data
Examinations
- Observations and clinical examinations performed and frequency:
- no data
- Specific biochemical examinations:
- no data
- Neurobehavioural examinations performed and frequency:
- Neurotoxic evidence was revealed by 2,4-pentanedione. Significant slowing of motor conduction velocities began to be observed in the 2,4-pentanedione group at 10th week. At 8th week, a significant decrease in sensory conduction velocities was also observed. In the 2,4-pentanedione group SCV values were slowed more than the MCV values. In the 2,4-pentanedione group, a significant decrease in nerve action potentials (NAP) amplitudes was observed at 16th week and that in muscle action potentials (MAP) amplitudes at 28th week. Residual latencies (RL) and motor distal latencies (DL) were not affected.
- Sacrifice and (histo)pathology:
- no data
- Other examinations:
- none
- Positive control:
- not applicable
- Statistics:
- not reported
Results and discussion
Results of examinations
- Clinical signs:
- not specified
- Mortality:
- not specified
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Gross pathological findings:
- not examined
- Neuropathological findings:
- effects observed, treatment-related
- Details on results:
- Neurotoxic evidence was revealed by 2,4-pentanedione. Significant slowing of motor conduction velocities began to be observed in the 2,4-pentanedione group at 10th week. At 8th week, a significant decrease in sensory conduction velocities was also observed. In the 2,4-pentanedione group SCV values were slowed more than the MCV values. In the 2,4-pentanedione group, a significant decrease in nerve action potentials (NAP) amplitudes was observed at 16th week and that in muscle action potentials (MAP) amplitudes at 28th week. Residual latencies (RL) and motor distal latencies (DL) were not affected.
Effect levels
- Dose descriptor:
- LOEL
- Effect level:
- 200 mg/kg bw/day
- Sex:
- not specified
- Basis for effect level:
- other: electrophysiology
- Remarks on result:
- other:
Applicant's summary and conclusion
- Conclusions:
- In this study, neurotoxic evidence was revealed by 2,4-Pentanedione.
- Executive summary:
A series of studies was made to clarify the relationship of 2,4-Pentanedione to neurotoxicity in terms of neuropathy and relative neurotoxic potentials using electrophysiological methods. A 200 mg/kg does was administered subcutaneously five days a weeks to one group of 8 rats. This program continued for 40 weeks. Electrophysiological studies of the effects of the compounds on the peripheral nervewere performed by measuring of maximum motor conduction velocities (MCV) and sensory conduction velocities (SCV) in the tail nerve of the rats. Residual latencies (RL), motor distal latencies (DL), amplitudes of the muscle action potentials (MAP) and amplitudes of nerve action potentials (NAP) were also estimated. Neurotoxic evidence was revealed by 2,4-pentanedione. Significant slowing of motor conduction velocities began to be observed in the 2,4-pentanedione group at 10th week. At 8th week, a significant decrease in sensory conduction velocities was also observed. In the 2,4-pentanedione group SCV values were slowed more than the MCV values. In the 2,4-pentanedione group, a significant decrease in nerve action potentials (NAP) amplitudes was observed at 16th week and that in muscle action potentials (MAP) amplitudes at 28th week. Residual latencies (RL) and motor distal latencies (DL) were not affected [IUCLID 3]
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.